公开(公告)号：US4459279A

公开(公告)日：1984-07-10

申请号：US409131

申请日：1982-08-18

Applicant: Herbert Stricker ,  Bernhard Freund ,  Heribert Harwalik ,  Karl L. Rominger ,  Siegfried Darda ,  Volkmar Haselbarth ,  Dietrich Arndts ,  Wolf D. Bechtel ,  Gerhard Bozler ,  Rolf Brickl ,  Peter Gruber

Inventor： Herbert Stricker ,  Bernhard Freund ,  Heribert Harwalik ,  Karl L. Rominger ,  Siegfried Darda ,  Volkmar Haselbarth ,  Dietrich Arndts ,  Wolf D. Bechtel ,  Gerhard Bozler ,  Rolf Brickl ,  Peter Gruber

IPC: A61K9/22 ,  A61K9/28 ,  A61K9/48 ,  A61K31/55 ,  A61K27/12

CPC classification number: A61K31/55 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/4808

Abstract: A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, where the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

Abstract translation: 药物剂量单位延迟形式，其具有恒定的pH独立的活性成分释放速率，由包含活性成分的核心和核心上的半渗透扩散涂层组成，其中涂层由水不溶性膜 - 前者，水溶性聚合物和最终掺入其中的酸不溶性聚合物。

公开(公告)号：US4427648A

公开(公告)日：1984-01-24

申请号：US389282

申请日：1982-06-17

Applicant: Rolf Brickl ,  Peter Gruber ,  Gottfried Schepky ,  Gerhard Bozler

Inventor： Rolf Brickl ,  Peter Gruber ,  Gottfried Schepky ,  Gerhard Bozler

IPC: A61K47/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/50 ,  A61K31/505 ,  A61K47/12 ,  A61P9/08 ,  A61P9/10 ,  A61K9/00 ,  A61K9/48 ,  A61K31/445

CPC classification number: A61K9/1617 ,  A61K31/505 ,  A61K9/2013 ,  A61K9/5078

Abstract: This invention relates to vehicles for the administration of dipyridamole. More specifically, this invention relates to a method of treating cardiovascular disorders in a host in need of such treatment which comprises administering to said host a cardiovascularly effective amount of a composition comprised of (i) dipyridamole or an acid addition salt thereof and (ii) at least one pharmacologically acceptable acid or acid substance, the total amount of acid from acid addition salt present and acid or acid substance being in a ratio of at least about 5 acid equivalents to 1 mol of dipyridamole, preferably in the form of particles having particle sizes of from about 0.1 to 2.0 mm.

Abstract translation: 本发明涉及给药双嘧达莫的载体。 更具体地，本发明涉及治疗需要这种治疗的宿主中的心血管疾病的方法，其包括向所述宿主施用心血管有效量的组合物，所述组合物包含（i）双嘧达莫或其酸加成盐，和（ii） 至少一种药理学上可接受的酸或酸物质，存在酸加成盐的酸的总量和酸或酸性物质的比例为至少约5当量酸与1摩尔双嘧达莫的比例，优选为具有颗粒的颗粒形式 尺寸为约0.1至2.0mm。

公开(公告)号：US4264771A

公开(公告)日：1981-04-28

申请号：US891456

申请日：1978-03-29

Applicant: Wolfgang Steglich ,  Rudolf Hurnaus ,  Peter Gruber ,  Boerries Kuebel

Inventor： Wolfgang Steglich ,  Rudolf Hurnaus ,  Peter Gruber ,  Boerries Kuebel

IPC: C07D263/42 ,  C07D265/10

CPC classification number: C07D263/42

Abstract: Manufacture of 4-substituted oxazolinone-(5) compounds, which are intermediates for .alpha.-substituted aminoacids, by alkylation of 2-substituted or 3,4-disubstituted oxozolinone-(5) compounds in an aprotic solvent in the presence of a tertiary amine.

Abstract translation: 通过在非质子传递溶剂中在叔胺存在下将2-取代或3,4-二取代的氧代唑啉酮（5）化合物烷基化制备4-取代的恶唑啉酮 - （5）化合物，它们是α-取代的氨基酸的中间体 。